245 related articles for article (PubMed ID: 38157255)
41. Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.
Wang Y; Zhang Y; Wang L; Zhang N; Xu W; Zhou J; Zhao Y; Zhu W; Zhang T; Wang L
Hepatol Int; 2022 Dec; 16(6):1435-1447. PubMed ID: 36065073
[TBL] [Abstract][Full Text] [Related]
42. An 8-gene predicting survival model of hepatocellular carcinoma (HCC) related to pyroptosis and cuproptosis.
Wang H; Wang N; Tang Z; Liu Q; Nie S; Tao W
Hereditas; 2023 Jul; 160(1):30. PubMed ID: 37464443
[TBL] [Abstract][Full Text] [Related]
43. Cuproptosis-related genes score: A predictor for hepatocellular carcinoma prognosis, immunotherapy efficacy, and metabolic reprogramming.
Nie G; Peng D; Wen N; Wang Y; Lu J; Li B
Front Oncol; 2023; 13():1096351. PubMed ID: 36845733
[TBL] [Abstract][Full Text] [Related]
44. A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma.
Zhang Q; Ma L; Zhou H; Zhou Y; Liu S; Li Q
Front Oncol; 2022; 12():1040736. PubMed ID: 36324575
[TBL] [Abstract][Full Text] [Related]
45. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1.
Quan Y; Li W; Yan R; Cheng J; Xu H; Chen L
Front Oncol; 2023; 13():1168769. PubMed ID: 37361595
[TBL] [Abstract][Full Text] [Related]
46. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
47. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
Dai L; Zhou P; Lyu L; Jiang S
BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
[TBL] [Abstract][Full Text] [Related]
48. Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients.
Peng H; Zou Z; Xiang Z; Lu X; Zhang Y; Peng X
Medicine (Baltimore); 2023 Aug; 102(34):e34741. PubMed ID: 37653738
[TBL] [Abstract][Full Text] [Related]
49. A novel prognostic scoring model based on copper homeostasis and cuproptosis which indicates changes in tumor microenvironment and affects treatment response.
Ma YL; Yang YF; Wang HC; Yang CC; Yan LJ; Ding ZN; Tian BW; Liu H; Xue JS; Han CL; Tan SY; Hong JG; Yan YC; Mao XC; Wang DX; Li T
Front Pharmacol; 2023; 14():1101749. PubMed ID: 36909185
[No Abstract] [Full Text] [Related]
50. Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma.
Cong T; Luo Y; Liu Y; Yang C; Yang H; Li Y; Li J; Li X
Front Genet; 2022; 13():1000997. PubMed ID: 36276933
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive analysis of cuproptosis-related long non-coding RNAs in prognosis, immune microenvironment infiltration and chemotherapy response of hepatocellular carcinoma.
Ren H; Zheng J; Zhu Y; Wang L; Liu J; Xu H; Dong J; Zhang S
Medicine (Baltimore); 2023 Dec; 102(50):e36611. PubMed ID: 38115286
[TBL] [Abstract][Full Text] [Related]
52. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
[TBL] [Abstract][Full Text] [Related]
53. Exploring the Role of DNA Methylation Located in Cuproptosis-Related Genes: Implications for Prognosis and Immune Landscape in Hepatocellular Carcinoma.
Zhu R; Wang X; Sun F; Zhu L; Guo W
Front Biosci (Landmark Ed); 2024 Mar; 29(3):123. PubMed ID: 38538282
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
Front Genet; 2023; 14():1094793. PubMed ID: 36891150
[No Abstract] [Full Text] [Related]
55. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
[TBL] [Abstract][Full Text] [Related]
56. The Role of Ferroptosis and Cuproptosis in Curcumin against Hepatocellular Carcinoma.
Liu Z; Ma H; Lai Z
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838613
[TBL] [Abstract][Full Text] [Related]
57. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
[TBL] [Abstract][Full Text] [Related]
58. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
59. Long non-coding RNAs in ferroptosis and cuproptosis impact on prognosis and treatment in hepatocellular carcinoma.
Wang K; Yang C; Xie J; Zhang X; Wei T; Yan Z
Clin Exp Med; 2024 Jun; 24(1):135. PubMed ID: 38907744
[TBL] [Abstract][Full Text] [Related]
60. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
